CATREN

UNIVADIS - CATREN /univadis/CATREN.md

ATC

Μορφές:
Μορφές: INJ.SO.INF

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2803051001013 305100101 CATREN INJ.SO.INF 2MG/ML BTx5 AMPS x 2,5ML 2.40 2.52 3.48
05/2018 2803051001020 305100102 CATREN INJ.SO.INF 2MG/ML BTx5 AMPS x 5ML 4.80 05.04 6.94
05/2018 2803051001037 305100103 CATREN INJ.SO.INF 2MG/ML BTx5 AMPS x 10ML 8.85 9.28 12.78
05/2018 2803051002010 305100201 CATREN INJ.SO.INF 5MG/ML BTx1 VIAL x 30ML 13.26 13.91 19.16
  • DRUGBANK - Cisatracurium Besylate
  • indication:

    For inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.

  • pharmacology:

  • mechanism:

    Cisatracurium Besylate binds to the nicotinic acetycholine (cholinergic) receptors in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrane remains depolarized and unresponsive to any other impulse, causing muscle paralysis.

  • toxicity:

    Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

  • absorprion:

  • halflife:

    Elimination half-life of 22 minutes.

  • roouteelimination:

    Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which atracurium represented only a minor fraction.

  • volumedistribution:

  • clearance: